Aperture Venture Partners

Aperture Venture Partners, LLC is a venture capital firm specializing in early stage investments. It seeks to invest in the healthcare and healthy living industries. Within healthcare industry, the firm invests in biopharmaceutical, biotechnology, healthcare services, healthcare information technology, diagnostics, drug discovery/delivery, and medical devices. Its investments in the healthy living category includes companies that offer products or services in the areas of personal care; weight management; complementary and alternative medicines; vitamins, minerals, and supplements; beverages; sporting goods; apparel; retail; and travel. The firm seeks to invest in companies based in the West Coast and North Eastern United States. It typically invests between $1 million and $4 million in its portfolio companies. The firm seeks to be the lead investor and can also o-invest. Aperture Venture Partners, LLC is based in New York, New York.
TN

Tony Natale

Managing Partner

Anthony Natale

Managing Partner

Eric Sillman

Managing Partner

PT

Paul Tierney

Managing Partner

48 past transactions

Channel Medsystems

Series C in 2015
Channel Medsystems, Inc. delivers women’s healthcare technologies for endometrial ablation. The company develops cryothermic technology and streamlined delivery system for female patients and healthcare providers. Its technology integrates cryothermic energy and the user controls into a self-contained and handheld device eliminating the need for a separate control unit or capital equipment. The company was incorporated in 2009 and is based in Emeryville, California.

Channel Medsystems

Series C in 2015
Channel Medsystems, Inc. delivers women’s healthcare technologies for endometrial ablation. The company develops cryothermic technology and streamlined delivery system for female patients and healthcare providers. Its technology integrates cryothermic energy and the user controls into a self-contained and handheld device eliminating the need for a separate control unit or capital equipment. The company was incorporated in 2009 and is based in Emeryville, California.

Nalu Medical

Venture Round in 2022
Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.

Bardy Diagnostics

Series B in 2019
Bardy Diagnostics, Inc. develops and manufactures cardiac monitoring devices. It offers Carnation Ambulatory Monitor (CAM), a cardiac patch monitor to capture low amplitude and frequency electrical signals that form the P-wave. The company also provides BDxCONNECT, a patient management system to the CAM patch, which offers a single system for creating, accessing, and managing patient CAM reports; and CAM reports that enables users to identify arrhythmia to aid clinical decision-making. Bardy Diagnostics, Inc. was incorporated in 2013 and is headquartered in Seattle, Washington. It has additional offices in Houston, Texas and New Providence, New Jersey.

MAKO Surgical

Series B in 2005
MAKO Surgical is a medical device company, markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures in the United States and internationally. The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specific osteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment. In 2011, The company was named the No.1 on the Technology Fast 500 as the fastest growing technology company by Deloitte and received the CSSEC Award for loyal, customer-focused staff members presented by the Technology Services Industry Association and ACE Award (Achievement in Customer Excellence) from MarketTools and Fast Tech Award as one of the 25 fastest growing technology companies in South Florida by South Florida Business Journal. MAKO Surgical was founded in 2004 and is headquartered in Florida, USA.

Spirox

Series B in 2015
Spirox is a California-based medical device company improving the quality of life for patients suffering from nasal obstruction. They are formerly known as Nasoform. Their first product, the LATERA absorbable nasal implant is designed to address one of the most common, yet undertreated, causes of nasal obstruction today, nasal valve collapse (NVC). The company intends to use the funds to complete development, seek US marketing authorization, and initiate product commercialization. Spirox was founded in 2011 and is headquartered in Menlo Park, California.

Metra Biosystems

Venture Round in 1992
Metra Biosystems develops and commercializes diagnostic products for the detection and management of metabolic bone and joint diseases and disorders.

Cortica

Venture Round in 2018
Cortica Inc. provides neurological therapies for children with autism and other neurodevelopmental challenges. It offers customized treatment programs for children with autism based on an in-depth understanding of the child's neurobiology and developmental profile. The company provides in-home, in-clinic, and telehealth services. Cortica Inc. was incorporated in 2014 and is based in San Diego, California. It has centers in Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village, California.

ENDOTRONIX

Series D in 2018
Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.

PetDx

Series B in 2021
PetDx operates as a molecular diagnostics company dedicated to revolutionizing the detection and ultimately treatment of cancer for pets. Founded in 2019, PetDx is focused on the development of non-invasive tests with customized assays and next-generation sequencing-based techniques, thereby providing veterinarians with early detection, characterization, and management of cancer cells.

MAKO Surgical

Series C in 2007
MAKO Surgical is a medical device company, markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures in the United States and internationally. The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specific osteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment. In 2011, The company was named the No.1 on the Technology Fast 500 as the fastest growing technology company by Deloitte and received the CSSEC Award for loyal, customer-focused staff members presented by the Technology Services Industry Association and ACE Award (Achievement in Customer Excellence) from MarketTools and Fast Tech Award as one of the 25 fastest growing technology companies in South Florida by South Florida Business Journal. MAKO Surgical was founded in 2004 and is headquartered in Florida, USA.

ENDOTRONIX

Series C in 2016
Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.

Altea Therapeutics

Series C in 2005
Altea Therapeutics Corporation develops and commercializes transdermal drug delivery systems. It offers PassPort patch, a skin patch that uses short bursts of focused thermal energy to create tiny channels in the surface of the skin and these channels permit the flow of proteins, peptides, carbohydrates, and small molecules into the body without the use of needles. The company also provides Transdermal vaccine patch, a delivery system for water-soluble drugs and proteins; disease prevention products; insulin skin patch, a non-injectable daily insulin product; and opioid patches that provide delivery of opioids and incorporates the layers of deterrents. Altea Therapeutics Corporation was formerly known as Altea Development Corporation. The company was founded in 1998 and is based in Atlanta, Georgia. As of May 9, 2012, Altea Therapeutics Corporation operates as a subsidiary of Nitto Denko Corp.

Redpoint Bio

Series A in 2003
Redpoint Bio is following a strategy focused on preserving the value of the License and Commercialization Agreement it entered into with International Flavors and Fragrances, Inc. (IFF), a global leader in the food and beverage industry. As part of this strategy, the Company continues its efforts to reduce its liabilities and sell its remaining assets. Given its lack of resources, the Company is not currently performing any research and development activities.

TherOx

Venture Round in 2005
TherOx, Inc. develops and manufactures dissolved oxygen delivery systems to improve the standard of care in heart attack treatments. It provides SSO2 therapy consists of TherOx DownStream system, a mobile hardware device that interfaces with the TherOx DownStream Cartridge and Console that controls cartridge operation wherein SSO2 solution is created and mixed with the patients blood to create superoxygenated blood for delivery to the coronary arteries. The company was founded in 1994 and is based in Irvine, California. As of June 18, 2019, TherOx, Inc. operates as a subsidiary of ZOLL Medical Corporation.

Cortica

Series C in 2021
Cortica Inc. provides neurological therapies for children with autism and other neurodevelopmental challenges. It offers customized treatment programs for children with autism based on an in-depth understanding of the child's neurobiology and developmental profile. The company provides in-home, in-clinic, and telehealth services. Cortica Inc. was incorporated in 2014 and is based in San Diego, California. It has centers in Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village, California.

Verix Health

Series A in 2019
Verix Health is developing a suite of actively steerable surgical devices enabling minimally invasive diagnosis and treatment of lesions in difficult-to-access anatomies. The company was founded by Professor Mark Yim, PhD and PCI Ventures at the University of Pennsylvania and incubated at the Pennovation Center in Philadelphia.

Xlumena

Series C in 2013
Xlumena, Inc. develops image-guided therapeutic endoscopy products for the field of medicine. It provides AXIOS Stent and Delivery System, a stent for the treatment of pancreatic pseudocysts; and NAVIX Access Device for the treatment of pancreatic pseudocysts. Xlumena, Inc. was formerly known as Novatech, Inc. The company was founded in 2008 and is based in Mountain View, California. As of April 2, 2015, Xlumena, Inc. operates as a subsidiary of Boston Scientific Corporation.

Channel Medsystems

Series B in 2013
Channel Medsystems, Inc. delivers women’s healthcare technologies for endometrial ablation. The company develops cryothermic technology and streamlined delivery system for female patients and healthcare providers. Its technology integrates cryothermic energy and the user controls into a self-contained and handheld device eliminating the need for a separate control unit or capital equipment. The company was incorporated in 2009 and is based in Emeryville, California.

Interlace Medical

Series C in 2009
Interlace Medical, Inc. is focused on designing and developing devices for the Interventional Gynecologist to perform office-based procedures to treat diseases and conditions traditionally requiring surgery in the operating room.

Altea Therapeutics

Series C in 2005
Altea Therapeutics Corporation develops and commercializes transdermal drug delivery systems. It offers PassPort patch, a skin patch that uses short bursts of focused thermal energy to create tiny channels in the surface of the skin and these channels permit the flow of proteins, peptides, carbohydrates, and small molecules into the body without the use of needles. The company also provides Transdermal vaccine patch, a delivery system for water-soluble drugs and proteins; disease prevention products; insulin skin patch, a non-injectable daily insulin product; and opioid patches that provide delivery of opioids and incorporates the layers of deterrents. Altea Therapeutics Corporation was formerly known as Altea Development Corporation. The company was founded in 1998 and is based in Atlanta, Georgia. As of May 9, 2012, Altea Therapeutics Corporation operates as a subsidiary of Nitto Denko Corp.

CardioMEMS

Venture Round in 2010
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.

V-Wave

Series C in 2020
V-Wave Ltd. develops percutaneous implantable therapeutic devices for chronic heart failure patients. It offers V-Wave Shunt, a biocompatible inter-atrial unidirectional implant that is used to treat chronic heart failure patients with preserved and reduced ejection fraction (diastolic and systolic heart failure). The company was founded in 2009 and is based in Caesarea, Israel with additional offices in Israel and the United States.
Lyric Pharmaceuticals Inc., a clinical-stage pharmaceutical company, develops therapeutics to improve the care of critically ill and hospitalized patients. The company develops ulimorelin, a macrocyclic agonist of the hormone ghrelin, as LP101 for the treatment of enteral feeding intolerance and for other disorders affecting critically ill patients in the ICU. It develops therapeutics for gastrointestinal indications. The company was founded in 2013 and is headquartered in South San Francisco, California.

Otonomy, Inc.

Series C in 2013
Otonomy was founded in 2008 by Avalon Ventures and experts in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes and from these, three product candidates have been advanced into development.

Tarsus Pharmaceuticals

Series B in 2020
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.

Avedro

Series D in 2013
Medical device and pharmaceutical company advancing the science and technology of corneal cross-linking

Cortica

Venture Round in 2020
Cortica Inc. provides neurological therapies for children with autism and other neurodevelopmental challenges. It offers customized treatment programs for children with autism based on an in-depth understanding of the child's neurobiology and developmental profile. The company provides in-home, in-clinic, and telehealth services. Cortica Inc. was incorporated in 2014 and is based in San Diego, California. It has centers in Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village, California.

Trevi Therapeutics, Inc.

Series C in 2017
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Its Haduvio (nalbuphine ER), which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease, as well as to treat chronic kidney disease-associated with pruritus. The company was founded in 2011 and is headquartered in New Haven, Connecticut.

Nina McLemore, LLC

Venture Round in 2004
Nina McLemore, LLC designs clothing for women. It offers jackets, fabrics, skirts, pants, hand crafted jewelries and accessories, suiting, casual wools, cottons, evening collections, essentials, and silks. The company provides its products through stores primarily in New York, San Francisco, Seattle, Aspen, Cleveland, Nantucket, Chestertown, and Easton. Nina McLemore, LLC was founded in 2002 and is based in New York, New York.

Neuros Medical

Series B in 2021
Neuros Medical, Inc., a neuromodulation company, develops proprietary neurostimulation therapies for unmet needs to patients worldwide. It offers Electrical Nerve Block, a technology for the elimination of chronic pain in various applications, including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine. The company also provides Neuros Altius System, a product that consists of an implantable generator with an integrated rechargeable battery, cuff electrode, and external devices. Neuros Medical, Inc. was incorporated in 2008 and is based in Willoughby Hills, Ohio.

Aclaris Therapeutics

Series C in 2015
Aclaris Therapeutics started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. It is committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist.

Xlumena

Series B in 2011
Xlumena, Inc. develops image-guided therapeutic endoscopy products for the field of medicine. It provides AXIOS Stent and Delivery System, a stent for the treatment of pancreatic pseudocysts; and NAVIX Access Device for the treatment of pancreatic pseudocysts. Xlumena, Inc. was formerly known as Novatech, Inc. The company was founded in 2008 and is based in Mountain View, California. As of April 2, 2015, Xlumena, Inc. operates as a subsidiary of Boston Scientific Corporation.

Cardiac Dimensions

Series B in 2018
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

CardioMEMS

Series F in 2009
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.

Inspire Medical Systems

Series E in 2014
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company also develops a novel, a closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire Medical Systems, Inc. was founded in 2007 and is headquartered in Golden Valley, Minnesota.

Cardiac Dimensions

Series C in 2020
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

Channel Medsystems

Series C in 2017
Channel Medsystems, Inc. delivers women’s healthcare technologies for endometrial ablation. The company develops cryothermic technology and streamlined delivery system for female patients and healthcare providers. Its technology integrates cryothermic energy and the user controls into a self-contained and handheld device eliminating the need for a separate control unit or capital equipment. The company was incorporated in 2009 and is based in Emeryville, California.

Ception Therapeutics

Series C in 2007
Ception Therapeutics is a biopharmaceutical company focused on the discovery and development of novel products to address areas of unmet medical need. Ception was founded by experienced pharmaceutical executives in order to develop and commercialize therapeutics in areas of significant unmet medical need.

Collegium Pharmaceutical

Venture Round in 2015
Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focused on building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform.

Ceptaris Therapeutics

Series D in 2012
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Cardiac Dimensions

Series A in 2015
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

Spirox

Series C in 2016
Spirox is a California-based medical device company improving the quality of life for patients suffering from nasal obstruction. They are formerly known as Nasoform. Their first product, the LATERA absorbable nasal implant is designed to address one of the most common, yet undertreated, causes of nasal obstruction today, nasal valve collapse (NVC). The company intends to use the funds to complete development, seek US marketing authorization, and initiate product commercialization. Spirox was founded in 2011 and is headquartered in Menlo Park, California.

ShiraTronics, Inc.

Series A in 2019
ShiraTronics is in the early stages of developing new innovative therapies to combat debilitating migraine headaches. The company is focused on commercializing novel neuromodulation technologies to treat this large unmet clinical need for patients and physicians. ShiraTronics is the first spinout from NuXcel a global medical device accelerator company.

Ceptaris Therapeutics

Series D in 2011
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Avedro

Series C in 2011
Medical device and pharmaceutical company advancing the science and technology of corneal cross-linking

Neuros Medical

Series A in 2017
Neuros Medical, Inc., a neuromodulation company, develops proprietary neurostimulation therapies for unmet needs to patients worldwide. It offers Electrical Nerve Block, a technology for the elimination of chronic pain in various applications, including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine. The company also provides Neuros Altius System, a product that consists of an implantable generator with an integrated rechargeable battery, cuff electrode, and external devices. Neuros Medical, Inc. was incorporated in 2008 and is based in Willoughby Hills, Ohio.